Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Shilpa Medicare Limited has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These are assigned to 2 distinct examiners and 2 distinct art units. HASTINGS, ALISON AZAR is the busiest examiner, with 1 pending office action. The data shows that the 2 pending actions are split evenly between the 2 examiners.
With 2 distinct art units involved, the company's Biotechnology & Pharmaceuticals applications are being reviewed by two different specialized groups. HASTINGS, ALISON AZAR is the busiest examiner, managing 1 pending office action, which accounts for half of the company's pending matters. This 1 to 1 ratio between pending actions and examiners means that each matter has a unique reviewer. The lack of concentration under a single examiner or art unit indicates that the company's current prosecution is divided between two separate officials. This spread allows for different examiner perspectives to be applied to the 2 pending actions currently in the portfolio. Practitioners should note that the 2 pending office actions are not concentrated under a single individual, but are instead spread across 2 distinct examiners.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HASTINGS, ALISON AZAR | 1 | 62.5% | +42.1% |
| PHAN, DOAN THI-THUC | 1 | 42.8% | +47.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18905163 | APIXABAN ORAL LIQUID DOSAGE FORMS | HASTINGS, ALISON AZAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18905163 | APIXABAN ORAL LIQUID DOSAGE FORMS | HASTINGS, ALISON AZAR | — |
| 18887827 | TRANEXAMIC ACID SPRAY FOR KNEE ARTHROPLASTY | PHAN, DOAN THI-THUC | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18905163 | APIXABAN ORAL LIQUID DOSAGE FORMS | HASTINGS, ALISON AZAR | 1627 | §103§112 | Non-Final OA | — | Pending | Oct 03, 2024 |
| 18887827 | TRANEXAMIC ACID SPRAY FOR KNEE ARTHROPLASTY | PHAN, DOAN THI-THUC | 1613 | §102§103§112DP | Non-Final OA | — | Pending | Sep 17, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShilpa Medicare Limited has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Alison Azar Hastings has the most, with 1 of Shilpa Medicare Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
